Nifty
Sensex
:
:
10906.95
36386.61
1.75 (0.02%)
12.53 (0.03%)

Pharmaceuticals & Drugs

Rating :
52/99

BSE: 530549 | NSE: SHILPAMED

398.25
0.65 (0.16%)
18-Jan-2019 | 3:57PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  397.55
  •  409.00
  •  390.00
  •  397.60
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  55146
  •  219.62
  •  609.00
  •  359.30

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 3,259.85
  • 26.27
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 3,377.09
  • 0.18%
  • 2.81

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 53.80%
  • 0.00%
  • 10.90%
  • FII
  • DII
  • Others
  • 0.02%
  • 13.15%
  • 22.13%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 16.84
  • 6.66
  • 3.26

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 21.16
  • 5.45
  • -1.12

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 33.48
  • 8.24
  • 0.78

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 25.65
  • 38.92
  • 38.80

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.02
  • 5.10
  • 5.03

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 18.05
  • 23.68
  • 25.08

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 18
Sep 17
Var%
Jun 18
Jun 17
Var%
Mar 18
Mar 17
Var%
Dec 17
Dec 16
Var%
Net Sales
162.28
203.99
-20.45%
198.17
165.87
19.47%
234.46
225.92
3.78%
185.53
183.58
1.06%
Expenses
124.75
147.35
-15.34%
143.44
133.26
7.64%
187.00
169.33
10.44%
158.38
148.74
6.48%
EBITDA
37.53
56.65
-33.75%
54.72
32.61
67.80%
47.46
56.59
-16.13%
27.14
34.83
-22.08%
EBIDTM
23.13%
27.77%
27.62%
19.66%
20.24%
25.05%
14.63%
18.97%
Other Income
3.15
5.30
-40.57%
4.36
4.88
-10.66%
6.78
9.47
-28.41%
5.07
4.03
25.81%
Interest
0.63
0.55
14.55%
0.58
0.55
5.45%
1.04
1.01
2.97%
0.46
0.73
-36.99%
Depreciation
10.00
8.32
20.19%
10.26
9.07
13.12%
10.77
8.00
34.62%
9.20
7.77
18.40%
PBT
56.12
53.08
5.73%
48.24
27.86
73.15%
42.42
52.51
-19.22%
22.55
30.37
-25.75%
Tax
11.39
11.94
-4.61%
9.64
9.02
6.87%
10.23
13.50
-24.22%
5.38
9.65
-44.25%
PAT
44.73
41.14
8.73%
38.61
18.84
104.94%
32.19
39.01
-17.48%
17.17
20.72
-17.13%
PATM
27.56%
20.17%
19.48%
11.36%
13.73%
17.27%
9.25%
11.29%
EPS
5.18
4.26
21.60%
4.13
2.77
49.10%
3.79
4.81
-21.21%
2.12
2.18
-2.75%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Net Sales
780.44
788.83
779.16
716.43
613.80
571.38
371.32
318.18
290.29
264.91
166.43
Net Sales Growth
0.14%
1.24%
8.76%
16.72%
7.42%
53.88%
16.70%
9.61%
9.58%
59.17%
 
Cost Of Goods Sold
314.33
355.87
371.81
366.19
323.16
313.26
213.95
183.22
162.98
136.30
93.51
Gross Profit
466.11
432.95
407.36
350.25
290.63
258.12
157.38
134.96
127.31
128.61
72.93
GP Margin
59.72%
54.89%
52.28%
48.89%
47.35%
45.17%
42.38%
42.42%
43.86%
48.55%
43.82%
Total Expenditure
613.57
637.60
617.55
556.44
487.38
455.40
301.63
257.08
219.70
188.58
144.25
Power & Fuel Cost
-
28.86
26.30
21.90
19.29
17.37
10.67
9.38
7.03
5.76
4.96
% Of Sales
-
3.66%
3.38%
3.06%
3.14%
3.04%
2.87%
2.95%
2.42%
2.17%
2.98%
Employee Cost
-
149.14
127.87
90.09
82.30
67.83
42.56
33.68
28.37
26.37
23.21
% Of Sales
-
18.91%
16.41%
12.57%
13.41%
11.87%
11.46%
10.59%
9.77%
9.95%
13.95%
Manufacturing Exp.
-
59.60
52.55
45.35
36.55
27.44
16.92
12.89
8.35
5.67
2.98
% Of Sales
-
7.56%
6.74%
6.33%
5.95%
4.80%
4.56%
4.05%
2.88%
2.14%
1.79%
General & Admin Exp.
-
22.47
16.95
14.11
10.64
9.53
9.51
7.87
5.64
5.12
4.24
% Of Sales
-
2.85%
2.18%
1.97%
1.73%
1.67%
2.56%
2.47%
1.94%
1.93%
2.55%
Selling & Distn. Exp.
-
6.37
4.75
7.27
5.99
7.29
4.43
3.19
4.63
6.31
3.26
% Of Sales
-
0.81%
0.61%
1.01%
0.98%
1.28%
1.19%
1.00%
1.59%
2.38%
1.96%
Miscellaneous Exp.
-
15.29
17.32
11.54
9.45
12.68
3.59
6.86
2.69
3.05
3.26
% Of Sales
-
1.94%
2.22%
1.61%
1.54%
2.22%
0.97%
2.16%
0.93%
1.15%
7.26%
EBITDA
166.85
151.23
161.61
159.99
126.42
115.98
69.69
61.10
70.59
76.33
22.18
EBITDA Margin
21.38%
19.17%
20.74%
22.33%
20.60%
20.30%
18.77%
19.20%
24.32%
28.81%
13.33%
Other Income
19.36
32.62
29.34
11.36
6.93
9.12
5.01
8.28
8.95
5.95
1.04
Interest
2.71
2.66
3.13
3.93
4.05
3.52
2.27
2.31
2.63
5.87
6.25
Depreciation
40.23
37.22
30.64
23.14
21.41
23.22
15.34
14.36
12.96
12.72
9.41
PBT
169.33
143.96
157.17
144.28
107.89
98.35
57.10
52.71
63.95
63.69
7.56
Tax
36.64
33.91
42.04
35.62
35.22
20.30
9.53
12.22
14.60
21.10
8.60
Tax Rate
21.64%
23.56%
27.54%
25.11%
32.66%
21.27%
16.72%
22.91%
22.83%
33.13%
113.76%
PAT
132.70
112.43
113.71
109.84
73.69
75.67
47.35
41.23
49.35
42.60
-1.04
PAT before Minority Interest
135.04
110.05
110.59
106.24
72.62
75.15
47.47
41.11
49.35
42.60
-1.04
Minority Interest
2.34
2.38
3.12
3.60
1.07
0.52
-0.12
0.12
0.00
0.00
0.00
PAT Margin
17.00%
14.25%
14.59%
15.33%
12.01%
13.24%
12.75%
12.96%
17.00%
16.08%
-0.62%
PAT Growth
10.85%
-1.13%
3.52%
49.06%
-2.62%
59.81%
14.84%
-16.45%
15.85%
-
 
Unadjusted EPS
15.22
13.20
13.58
13.59
19.22
20.57
12.90
16.89
21.48
19.34
-0.48

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Shareholder's Funds
1,085.03
986.90
639.26
546.94
396.45
320.42
275.98
224.68
100.20
58.67
Share Capital
8.15
8.01
7.71
7.71
7.36
4.90
4.90
4.80
4.40
4.40
Total Reserves
1,076.88
978.88
631.55
539.23
389.09
315.52
271.07
213.85
95.80
54.26
Non-Current Liabilities
185.10
251.26
67.23
154.15
104.53
98.51
31.13
31.85
91.47
123.49
Secured Loans
67.09
141.20
0.03
71.03
37.43
70.47
5.07
11.42
73.09
108.56
Unsecured Loans
1.03
1.30
0.00
31.30
30.05
0.00
0.00
0.00
4.96
4.12
Long Term Provisions
20.21
16.89
13.96
11.75
9.93
6.92
6.34
5.71
0.00
0.00
Current Liabilities
266.70
236.90
222.07
189.06
166.84
123.77
121.14
80.21
56.17
38.64
Trade Payables
110.47
111.86
106.48
75.50
92.98
51.26
56.72
27.90
41.06
24.26
Other Current Liabilities
53.70
28.03
36.49
49.32
38.23
23.38
20.34
16.65
1.37
6.39
Short Term Borrowings
98.12
92.41
74.10
58.47
30.27
45.07
41.24
33.15
0.00
0.00
Short Term Provisions
4.41
4.60
5.00
5.77
5.37
4.06
2.83
2.51
13.75
7.99
Total Liabilities
1,531.61
1,472.22
930.89
904.54
677.83
551.42
433.11
338.21
247.84
220.80
Net Block
534.20
491.93
393.41
316.06
294.42
180.67
166.61
146.25
147.55
144.51
Gross Block
793.24
704.89
582.20
476.34
448.38
300.89
271.30
232.84
221.72
212.07
Accumulated Depreciation
259.04
212.96
188.79
160.28
153.96
120.22
104.70
86.59
74.18
67.56
Non Current Assets
859.67
742.33
576.68
576.77
443.89
339.18
244.95
159.79
153.53
148.62
Capital Work in Progress
209.85
140.51
91.90
221.62
111.03
129.15
57.71
2.72
3.29
3.65
Non Current Investment
20.79
27.99
34.15
0.19
0.21
0.14
0.11
3.65
2.70
0.46
Long Term Loans & Adv.
69.98
77.09
51.86
38.74
38.18
28.82
20.17
6.62
0.00
0.00
Other Non Current Assets
24.86
4.80
5.36
0.16
0.06
0.40
0.34
0.00
0.00
0.00
Current Assets
671.94
729.88
354.21
327.61
233.74
211.99
187.87
178.39
94.25
72.08
Current Investments
119.54
224.62
59.63
65.35
10.14
50.28
68.02
0.00
0.00
1.21
Inventories
188.71
190.00
134.23
130.78
123.25
74.33
67.32
43.33
50.43
32.09
Sundry Debtors
220.33
170.93
125.43
81.37
67.96
41.79
40.53
40.13
34.89
23.70
Cash & Bank
73.83
100.39
11.03
18.42
9.19
16.87
2.27
87.20
2.34
4.06
Other Current Assets
69.53
22.00
15.00
26.78
23.20
28.72
9.72
7.72
6.58
11.03
Short Term Loans & Adv.
43.17
21.95
8.90
4.91
3.23
2.86
3.01
1.56
3.24
5.45
Net Current Assets
405.24
492.98
132.14
138.55
66.90
88.22
66.73
98.18
38.08
33.44
Total Assets
1,531.61
1,472.21
930.89
904.54
677.83
551.42
433.10
338.21
247.84
220.80

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Cash From Operating Activity
44.92
37.48
128.70
68.81
70.04
43.64
56.73
40.86
53.52
29.74
PBT
136.77
146.49
140.36
107.84
95.45
57.00
53.51
64.13
63.69
7.56
Adjustment
18.83
17.19
20.61
26.46
19.62
11.52
10.19
10.42
16.10
24.43
Changes in Working Capital
-69.66
-92.61
-2.70
-40.11
-23.44
-13.90
0.77
-21.04
-13.93
2.39
Cash after chg. in Working capital
85.94
71.08
158.27
94.19
91.62
54.62
64.46
53.51
65.86
34.38
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-41.02
-33.60
-29.56
-25.38
-21.58
-10.98
-7.73
-12.61
-12.38
-4.64
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-8.43
-262.23
-109.20
-195.18
-48.93
-95.21
-152.31
7.77
-18.26
-52.66
Net Fixed Assets
-136.76
-172.23
-92.14
-78.46
-61.02
-83.52
-79.20
-5.23
-13.38
-50.34
Net Investments
95.51
-172.72
-14.09
-64.38
12.08
13.84
-73.05
-24.39
-3.67
-0.01
Others
32.82
82.72
-2.97
-52.34
0.01
-25.53
-0.06
37.39
-1.21
-2.31
Cash from Financing Activity
-61.24
312.70
-19.65
135.05
-28.34
66.31
10.02
35.93
-36.69
12.40
Net Cash Inflow / Outflow
-24.75
87.95
-0.15
8.68
-7.23
14.74
-85.56
84.56
-1.43
-10.52
Opening Cash & Equivalents
99.97
7.05
3.61
9.19
16.87
2.27
87.83
2.65
3.77
14.57
Closing Cash & Equivalent
73.83
99.97
6.43
18.42
9.19
16.87
2.27
87.20
2.34
4.06

Financial Ratios

Consolidated /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Book Value (Rs.)
133.09
123.17
82.91
70.92
107.72
43.52
74.94
60.67
30.31
8.86
ROA
7.33%
9.20%
11.58%
9.18%
12.23%
9.64%
10.66%
16.84%
18.18%
-0.52%
ROE
10.62%
13.60%
17.92%
15.40%
20.98%
15.93%
16.63%
30.96%
53.67%
-1.84%
ROCE
11.71%
15.91%
19.90%
17.90%
20.48%
15.04%
18.02%
28.98%
39.81%
8.75%
Fixed Asset Turnover
1.06
1.22
1.36
1.34
1.54
1.32
1.28
1.30
1.25
0.95
Receivable days
90.21
69.00
52.26
43.99
34.62
39.70
45.47
46.24
39.56
46.47
Inventory Days
87.32
75.49
66.97
74.84
62.33
68.31
62.38
57.79
55.71
69.93
Payable days
63.49
60.89
60.10
62.86
57.06
63.94
59.10
55.44
61.43
55.15
Cash Conversion Cycle
114.04
83.61
59.13
55.97
39.90
44.07
48.76
48.59
33.83
61.26
Total Debt/Equity
0.18
0.24
0.14
0.34
0.30
0.41
0.22
0.26
0.78
1.92
Interest Cover
55.10
49.69
37.07
27.63
28.09
26.13
24.13
25.28
11.85
2.21

News Update:


  • Shilpa Medicare gets USFDA’s approval for Imatinib Mesylate Tablets
    18th Jan 2019, 11:05 AM

    According to IQVIA MAT Q2 2018 data, the US market for Imatinib Mesylate Tablets, 100 mg and 400 mg is approximately $885 million

    Read More
  • Shilpa Medicare receives approval from USFDA for Irinotecan HCL Injection
    1st Jan 2019, 09:37 AM

    Irinotecan injection is used in the treatment of patients with metastatic carcinoma of the colon or rectum

    Read More
  • Shilpa Medicare to acquire 5.22% stake in Prathijna Sustainable solutions
    16th Nov 2018, 11:06 AM

    The Board of Directors of the company at their meeting held on November 14, 2018, decided the same

    Read More
  • Shilpa Medicare gets tentative ANDA approval for Dimethyl Fumarate DR Capsules
    16th Nov 2018, 10:35 AM

    ANDA is a first to file submission made on NCE-1 dated March 27, 2017

    Read More
  • Shilpa Medicare - Quarterly Results
    14th Nov 2018, 13:45 PM

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.